2CJ-27688-20535
4 vaccinations
5 coded responses
46 check-ins
5 free-text entries
2 call cases
- Sex
- Female
- Age at first dose
- 36-40
- ZIP prefix
- 027 / MA
- Registered
- 2021-01-16
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-01-16
Registered in v-safe
-
2021-01-16
Dose 1 — Pfizer-BioNTech
-
2021-01-16
Health check-in — day 0, dose 1Feeling: Good · Site: Pain · Headache, Fatigue or tirednessAdult check-in
- 2021-01-17
- 2021-01-18
- 2021-01-20
- 2021-01-21
- 2021-01-23
- 2021-01-31
-
2021-02-06
Dose 2 — Pfizer-BioNTech
-
2021-02-09
Survey response — days 1–6 daily, dose 2MedDRA: Injection site reaction — Feeling: Fair · Site: Pain, Redness, Itching · Headache, Fatigue or tiredness, Nausea · Be unable to do your normal daily activitiesFree text: Muscle spasm near injection siteMedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
-
2021-02-10
Survey response — days 1–6 daily, dose 2MedDRA: Injection site erythema — Feeling: Fair · Site: Pain, Redness, ItchingFree text: Red spotted area near injection siteMedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
-
2021-02-11
Health check-in — days 1–6 daily, dose 2Feeling: Good · Site: Redness, Itching · Rash, not including the immediate area around the injection siteAdult check-in
-
2021-02-12
Health check-in — days 1–6 daily, dose 2Feeling: Good · Site: Itching · Rash, not including the immediate area around the injection siteAdult check-in
-
2021-02-13
Health check-in — day 7, dose 2Feeling: Good · Site: Itching · Rash, not including the immediate area around the injection siteAdult check-in
- 2021-02-20
- 2021-02-27
- 2021-03-06
- 2021-03-13
-
2021-03-20
Survey response — day 42, dose 2MedDRA: Vertigo — Feeling: Good · Be unable to work, Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · Telehealth, virtual health, or email health consultation, Emergency room or emergency department visitFree text: VertigoMedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
-
2021-03-20
Report sent to call center — day 42, dose 2Be unable to work · Be unable to do your normal daily activities · Get care from a doctor or other healthcare professional1 call case(s)
-
2021-05-08
Survey response — 3 months, dose 2MedDRA: Vertigo — Feeling: Good · Be unable to work, Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · Telehealth, virtual health, or email health consultation, Emergency room or emergency department visitFree text: VertigoMedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
-
2021-05-08
Report sent to call center — 3 months, dose 2Be unable to work · Be unable to do your normal daily activities · Get care from a doctor or other healthcare professional1 call case(s)
- 2021-08-07
-
2021-12-22
Call successfulReported to VAERS voluntarily prior to GDIT contact
-
2022-01-08
Dose 3 — Pfizer-BioNTech
-
2022-01-09
Health check-in — days 1–6 daily, dose 3Feeling: Fair · Site: Pain · Fever · Chills, Headache, Fatigue or tiredness, NauseaAdult check-in
- 2022-01-10
- 2022-01-11
- 2022-01-12
-
2022-01-13
Health check-in — days 1–6 daily, dose 3Feeling: Fair · Headache, Nausea, Diarrhea · Be unable to work or attend schoolAdult check-in
- 2022-01-14
- 2022-01-17
- 2022-01-22
- 2022-01-31
-
2022-02-05
Survey response — day 28, dose 3MedDRA: Cough, Headache, Oropharyngeal pain, Rhinorrhoea — Feeling: Poor · Be unable to work or attend school, Be unable to do your normal daily activitiesFree text: Sore throat, cough, runny nose, headacheMedDRA releases: 2024-11 · check-in free text available
- 2022-02-12
- 2022-02-19
- 2022-04-09
- 2022-07-09
-
2022-11-12
Dose 4 — Pfizer-BioNTech
-
2022-11-13
Health check-in — days 1–6 daily, dose 4Feeling: Fair · Site: Pain · Fatigue or tiredness, NauseaAdult check-in
- 2022-11-14
- 2022-11-15
- 2022-11-16
- 2022-11-18
- 2022-11-19
- 2022-11-26
- 2022-12-03
- 2022-12-10
- 2022-12-17
- 2022-12-24
- 2023-02-11
- 2023-05-13
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-01-16 | Pfizer-BioNTech | |
| 2 | 2021-02-06 | Pfizer-BioNTech | |
| 3 | 2022-01-08 | Pfizer-BioNTech | No |
| 4 | 2022-11-12 | Pfizer-BioNTech | No |
Call center
| Reported | Outcome | VAERS-related outcome |
|---|---|---|
| 2021-03-20 | Successful | Reported to VAERS voluntarily prior to GDIT contact |
| 2021-05-08 | Successful 2021-12-22 |
Reported to VAERS voluntarily prior to GDIT contact |
Free text
Release 3 — days 1–6 daily, dose 2
Systemic reaction (other): Muscle spasm near injection site
Release 4 — days 1–6 daily, dose 2
Systemic reaction (other): Red spotted area near injection site
Release 6 — day 42, dose 2
Symptoms: Vertigo
Release 8 — 3 months, dose 2
Symptoms: Vertigo
Release 11 — day 28, dose 3
Symptoms: Sore throat, cough, runny nose, headache
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Cough | · | · | ✓ |
| SD | Headache | · | · | ✓ |
| SD | Oropharyngeal pain | · | · | ✓ |
| SD | Rhinorrhoea | · | · | ✓ |
| SD | Vertigo | ✓ | ✓ | ✓ |
| SRO | Injection site erythema | ✓ | ✓ | ✓ |
| SRO | Injection site reaction | ✓ | ✓ | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release